$BMRN News

BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET

Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122

Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?

1cBio Received Shareholder Proceeds Upon Closing of BioMarin Pharmaceutical Inc.'s Acquisition of Alesta Therapeutics

Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) Screens as a Decent Value Stock on Cheap Forward Earnings

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

BioMarin Pharmaceutical To Present New Data From Studies Of VOXZOGO In Children With Achondroplasia And Hypochondroplasia And From Studies Of Investigational Long-Acting BMN 333 At American Society For Bone And Mineral Research Meeting; New Analysis Showcases Impact Of VOXZOGO In Foramen Magnum And Craniocervical Junction Growth

BioMarin Pharmaceutical (BMRN), What Is Behind The Latest Attention?

BioMarin Pharmaceutical Expects Q3 Pre-Tax Charges Of $283M For Bought IPR&d Expense; Expects $1.5 Unfavorable Impact To GAAP And Non-gaap Diluted EPS For Q3; Expects Total Pre-Tax Charges Of $320M For FY26 From Alesta Acquisition; Expects $1.55 Unfavorable Impact To GAAP And Non-Gaap Diluted EPS For FY26

BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress

BioMarin Pharmaceutical Presents New Efficacy Data On POMBILITI + OPFOLDA In Pompe Disease At 31st Annual Congress Of World Muscle Society; No New Safety Signals Identified

The Strategic Financial Case for BioMarin Pharmaceutical (BMRN)

BioMarin and Profluent partner on AI-designed enzyme therapies

BioMarin and Profluent partner on AI-designed enzyme therapies

Profluent Partners With BioMarin to Design Novel Medicines Using AI

What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)?

Did VOXZOGO’s Hypochondroplasia Win and New R&D Hire Just Reframe BioMarin’s (BMRN) Investment Narrative?

BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone